Francqui Chair 2016-2017 has started

Share this article

Last Tuesday, the international Francqui Chair 2016-2017 was inaugurated with a lecture on ‘Changing the face of modern medicine: gene therapy and gene editing’, by Thierry VandenDriessche at Ghent University. 

You can take part in the following lectures at Auditorium 1.008, building S2, Campus Sterre, Krijgslaan 281, 9000 Ghent, from 16.00 – 17.15h:

  • Wednesday February 22, 2017
    Fixing broken genes by ”cutting-edge” gene therapy and gene editing
  • Wednesday March 1, 2017
    Curing hemophilia: from Royal disease to gene therapy
  • Wednesday March 8, 2017
    Gene therapy flexes its muscles: new prospects for treating hereditary muscular diseases
  • Wednesday March 15, 2017
    Gene therapy and gene editing for hematopoietic disorders: a trailblazer for the field
  • Wednesday March 22, 2017
    Weaponising the immune system by gene therapy and gene editing to combat cancer
  • Wednesday April 19, 2017
    Fighting neurodegenerative disorders with gene therapy
  • Wednesday April 26, 2017
    Seeing the light: gene therapy and gene editing for ocular diseases

Subscribe here.

VandenDriessche is tenured Professor at the Faculty of Medicine and Pharmacy and Director of the Department of Gene Therapy and Regenerative Medicine of the Free University of Brussels (VUB).
He is also Professor at the Faculty of Medicine of the University of Leuven (KU Leuven). For the past 30 years, he has dedicated his scientific career to the field of gene therapy. His research is at the nexus of fundamental and translational research and technology development in gene therapy and gene editing for hereditary diseases and cancer.
He is European Editor of Human Gene Therapy and a member of the Board of Directors of the American Society of Gene & Cell Therapy.
He previously served as President of the European Society of Gene & Cell Therapy. Prior to his current affiliations, he has been at the Weizmann Institute for Science (Israel), National Heart Lung & Blood Institutes (NIH, USA), National Center for Human Genome Research (NIH, USA) and Flanders Institute of Biotechnology (VIB).
He is the recipient of the 2012 Outstanding Achievement Award of the European Society of Gene & Cell Therapy, Molecule of the Year Award, the Em Prof Dr Marc Baron Verstraete Award in Hemato-angiology (Royal Academy of Medicine) and the 2016 Henri Chaigneau Career Award of the French Hemophilia Society.
He published over 120 peer-reviewed publications, several in high-impact factor journals, and has been regularly invited as keynote or plenary speaker at international conferences.